Stephanie A.S. Harrington has more than 14 years of management experience in the medical device industry, with a focus on product and process development. In her current role, Harrington is responsible for new product development, engineering operations, corporate regulatory and quality affairs, as well as the exploration and implementation of new business opportunities for Mentor, Ohio-based Frantz Medical Group. Frantz (www.frantzgroup.com) is an integrated group of companies dedicated to the development and manufacturing of medical devices and diagnostics.
As part of her current duties, Harrington has assumed leadership roles in several new ventures, including serving as chief operating officer for two start-up companies, VasoStar Inc. and NanoMed Systems Inc. NanoMed Systems, in partnership with Medtronic Cardiovascular, is working to further develop and commercialize its proprietary nanoporous thin film coating process for use in several medical applications.
Harrington also serves as VP of research and business development for Merlot OrthopediX Inc., a joint equity partnership between Frantz Medical and the Cleveland Clinic. Merlot OrthopediX is focused on developing and commercializing innovative orthopedic devices.
Prior to joining Frantz Medical, Harrington served as VP of regulatory and clinical affairs at Imalux Corp., a medical device company commercializing a novel imaging modality, optical coherence tomography. At Imalux, she established the corporate regulatory strategy and development plan for the imaging system, ensured quality compliance, and initiated and monitored clinical studies. Under her direction, the company achieved 510(k) clearances for their imaging system and accompanying disposable sheath, the first platform OCT imaging medical device to enter the domestic market.
Before joining Imalux, Harrington held several positions of increasing responsibility at Steris Corp. Steris is a global leader in infection control and surgical support products and services, with more than $1.25 billion in annual revenue. For the final four years of her tenure at Steris, she served as a director in research and development, responsible for product development of medical device reprocessing systems, supervising 40 scientists and engineers with a fiscal budget of $5 million.
Harrington earned a Master's degree in chemical engineering from